University of Iowa News
March 14, 2006
NIH Selects UI To Test Modified Bird Flu Vaccine
The National Institutes of Health has selected the University of Iowa as one of six sites to study whether a vaccine additive can make a vaccine for the H5N1 strain of avian (bird) influenza more effective.
The H5N1 subtype of influenza A virus has spread through bird populations in other countries and caused severe infections and some deaths in small numbers of humans that became sick with the strain, usually from direct contact with infected birds.
The subtype has not yet been detected in any birds, animals or humans in the United States. However, the virus has spread to a number of new countries over the past few months and could eventually mutate into a form that spreads easily among people, said Patricia Winkour, M.D., associate professor of internal medicine in UI Hospitals and Clinics and the UI Roy J. and Lucille A. Carver College of Medicine, who is leading the UI portion of the study.
"The emergence of this influenza virus makes it urgent for us to prepare for a potential influenza pandemic," said Winokur, who also is a physician and researcher with the Veterans Affairs Iowa City Health Care System.
An inactivated vaccine was developed for the H5N1 strain. Although previous research showed that the vaccine is well tolerated, the immune response was not as strong as expected, even among people given the highest dose of the vaccine. Two doses currently are needed to prompt even a moderate immune response, making it difficult to stockpile vaccine for millions of people.
As a result, the researchers want to see if a vaccine additive, called an adjuvant, can help produce a strong response while using a smaller amount of vaccine per person.
"The new study will determine whether the adjuvant aluminum hydroxide can improve the antibody response to the vaccine," Winokur said. "Adjuvants already are used in many vaccines and can produce a stronger immune response than vaccine proteins used alone."
The research team will compare the immune responses and reactions of participants given one of eight different doses of the bird flu vaccine. Four different dilutions of influenza vaccine will include the adjuvant and will be compared to comparable vaccination doses that do not contain the adjuvant.
A total of 600 participants will be enrolled in the study, including 100 at the UI. The study is led by the University of Maryland. The other study sites are Cincinnati Children's Hospital Medical Center, Baylor College of Medicine in Houston, University of Rochester and University of Washington.
For more information on the study, see this call for participants UI Study On Bird Flu Invites Participants Age 65 And Older.
University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at www.uihealthcare.com.
STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 5224-1178
STUDY CONTACT: Bird Flu Study, 319-384-7245
MEDIA CONTACT: Becky Soglin, 319-335-6660, firstname.lastname@example.org